Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

J Clin Invest. 2000 Apr;105(8):1045-7. doi: 10.1172/JCI9872.
No abstract available

Publication types

  • Comment

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms / drug therapy
  • Carcinoma, Lewis Lung / drug therapy
  • Cyclohexanes
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use
  • Female
  • Humans
  • Maximum Tolerated Dose
  • Mice
  • Neovascularization, Pathologic / drug therapy*
  • Neuroblastoma / blood supply
  • Neuroblastoma / drug therapy
  • O-(Chloroacetylcarbamoyl)fumagillol
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • Receptor Protein-Tyrosine Kinases / immunology
  • Receptors, Growth Factor / antagonists & inhibitors
  • Receptors, Growth Factor / immunology
  • Receptors, Vascular Endothelial Growth Factor
  • Sesquiterpenes / adverse effects
  • Sesquiterpenes / therapeutic use
  • Tumor Cells, Cultured
  • Vinblastine / pharmacology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Cyclohexanes
  • Receptors, Growth Factor
  • Sesquiterpenes
  • Vinblastine
  • Cyclophosphamide
  • Receptor Protein-Tyrosine Kinases
  • Receptors, Vascular Endothelial Growth Factor
  • O-(Chloroacetylcarbamoyl)fumagillol